The Israeli energy-device maker is exploring a potential acquisition, reflecting ongoing PE and strategic buyer interest in aesthetic-device platforms.
InMode announced receipt of an unsolicited acquisition proposal, confirming that a buyer—identity undisclosed—has expressed interest in acquiring the Israeli energy-device company. InMode manufactures RF microneedling, fractional RF, and other modalities under brands including Morpheus8 and EvoluTION, and has built significant market share in the U.S. aesthetic and surgical markets.
The proposal underscores ongoing appetite among PE firms and strategic buyers (device roll-ups, larger medtech companies) to consolidate aesthetic-device platforms. InMode's profitability, recurring revenue model (consumable tips and handpieces), and installed base make it an attractive target. The company's board is evaluating the proposal; no deal is certain.
Unsolicited proposal signals PE and strategic buyer appetite for consolidated device platforms.
For practices using InMode devices, a change of control could affect pricing, support, and product-development roadmap. Historically, PE-backed consolidations have led to price increases and tighter rebate terms as acquirers seek margin expansion. Monitor developments closely.
Source: original report ↗
Frequently asked questions
What happens to InMode device pricing if the company gets acquired?
Historically, PE-backed consolidations in medtech have led to price increases and tighter rebate terms as acquirers prioritize margin expansion. Practices should monitor the deal terms closely and lock in current pricing agreements before any acquisition closes, as consumable tips and handpieces—InMode's recurring revenue model—are typical targets for margin pressure.
Will InMode stop making Morpheus8 and EvoluTION if acquired?
No immediate discontinuation is likely, as InMode's brands (Morpheus8, EvoluTION, and others) are core assets that attracted the buyer's interest. However, product-development roadmaps, feature updates, and support priorities may shift under new ownership, so practices should stay informed about any changes to R&D strategy post-close.
Could an InMode acquisition affect customer support and service?
Yes—consolidations often restructure support operations to cut costs or integrate systems. Practices should document their current support contacts and SLAs now, and clarify support continuity and response times in writing before any deal closes to protect service levels.
Is InMode definitely going to be acquired?
No. InMode's board is evaluating an unsolicited proposal, but no deal is certain or guaranteed. The company may reject the offer, negotiate different terms, or explore other options. Practices should continue normal operations and avoid making major device decisions based on acquisition speculation.
Why are PE firms and device companies interested in buying InMode?
InMode is profitable, has significant U.S. market share in aesthetic and surgical RF devices, and generates recurring revenue from consumable tips and handpieces. This recurring revenue model and installed base of practices make it an attractive consolidation target for PE roll-ups and larger medtech companies seeking to expand their aesthetic-device portfolios.
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.
